Can you take TB-500 orally?

No. There is no published human study showing that oral TB-500 survives digestion, enters the bloodstream intact, or produces a clinical result. Peptides face stomach acid, digestive enzymes, and the gut wall. A specially engineered oral formulation might address those barriers, but a capsule label by itself does not show that the necessary protection or absorption has been tested.

Do TB-500 capsules work?

No human evidence shows that TB-500 capsules work. FDA's 2026 review found no study in which TB-500 was administered to a person by any route, while the newest direct study used injections in rats. A seller's ingredient list cannot establish the peptide's identity, stability through digestion, absorption into human blood, or a health outcome.

Is TB-500 the same as thymosin beta-4?

No. FDA's 2026 briefing identifies TB-500 as a synthetic 7-amino-acid fragment of thymosin beta-4. Thymosin beta-4 is the naturally occurring 43-amino-acid parent peptide. Online pages often blur the names, but evidence from the larger molecule cannot automatically be assigned to the shorter fragment, especially when the route and formulation also differ.

Is oral TB-500 comparable to oral BPC-157?

Not directly. BPC-157 has animal experiments that used oral or stomach-delivered routes, although controlled human capsule evidence is still missing. TB-500 has no comparable oral animal or human data. Peptides differ in structure and stability, so evidence that one peptide survived a particular formulation or route cannot show that another peptide will do the same.

Is TB-500 an approved medicine?

No. TB-500 has never been FDA-approved in the United States, and the compounded formulation offered here is not FDA-approved. FDA's 2026 assessment found no human TB-500 exposure or safety data by any route. A licensed provider may still prescribe a compounded formulation after an individual medical review; FDA status does not replace that patient-and-doctor decision.

Can tested athletes use TB-500?

No. The World Anti-Doping Agency's 2026 Prohibited List names TB-500 under growth factors and growth-factor modulators. It is prohibited at all times, including both in competition and out of competition. A prescription does not by itself change anti-doping rules, so an athlete subject to testing needs guidance from the relevant sport or anti-doping authority.

Oral TB-500: Why Capsules Lack Human Evidence

Oral TB-500 has no human evidence behind it. No study has measured whether a TB-500 capsule delivers intact peptide into the bloodstream, and FDA's 2026 review found no human study of TB-500 by any route. Peptides are short chains of amino acids, the building blocks of proteins. The gut is built to cut them apart. A capsule would need a tested way to protect the peptide and help it cross the intestinal wall. No published TB-500 capsule study has shown that.

First, TB-500 and thymosin beta-4 are not identical

This mix-up is behind a lot of confident claims about TB-500 pills. Thymosin beta-4, or Tβ4, is a naturally occurring peptide made of 43 amino acids. FDA's May 15, 2026 TB-500 briefing identifies TB-500 as a synthetic 7-amino-acid fragment from positions 17 through 23 of that larger peptide. It also notes that online sources use the names inconsistently.

The distinction matters. A result produced by the full 43-amino-acid peptide doesn't automatically belong to its 7-amino-acid fragment. Even the well-known Goldstein and Kleinman review covers full-length Tβ4, including its interaction with actin, part of a cell's internal scaffolding. Our plain guide to thymosin beta-4 keeps the parent peptide and fragment separate.

Why oral TB-500 is a hard delivery problem

Swallowing a peptide isn't the same as swallowing an ordinary tablet. Stomach acid can destabilize it. Proteases, the digestive enzymes that cut proteins and peptides, can break it into smaller pieces. Whatever remains still has to cross the gut wall, which generally resists large, water-loving molecules.

A 2025 review of oral peptide delivery describes the result: most unprotected peptides have very low bioavailability, meaning very little reaches the bloodstream intact. Successful oral peptide medicines need purpose-built technology such as protective coatings, enzyme blockers, or absorption enhancers. That general barrier doesn't prove a specific TB-500 capsule absorbs poorly. It tells us what a capsule study would need to measure. No such human study has been published.

What the wound, heart, and tendon studies actually used

The older wound-healing and cardiac literature is mostly about full-length Tβ4 in animals. A Kleinman review of those animal studies describes topical delivery, meaning applied to a surface, and systemic delivery, meaning introduced so it can circulate through the body. It does not establish that an oral capsule delivers Tβ4 or TB-500.

A June 19, 2026 scoping review screened 1,772 records and included 80 studies. Seventy studied full-length Tβ4, while only one directly studied TB-500. The review mapped 19 human studies, mainly in eye, skin, and soft-tissue settings, but none administered the TB-500 fragment to people. It also found no human intervention using either molecule for tendon, ligament, or muscle injury.

As of September 9, 2026, the day this article was written, the newest direct TB-500 study still does not test a pill. The July 23, 2026 rat Achilles-tendon paper used daily intraperitoneal injections, which go into the abdominal cavity, for four weeks. It included 32 rats split into four groups, with only four tendons per group assigned to each endpoint. The findings may guide further animal research, but they cannot answer whether a human absorbs TB-500 from a capsule. The study also tested TB-500 with BPC-157, the pairing often called the Wolverine peptide stack, and found no added advantage for the combination over the individual groups.

What a TB-500 capsule listing really tells you

A capsule listing tells you what the seller says is in the bottle. It does not show that the stated peptide identity was independently confirmed, that the molecule stayed intact through storage and digestion, or that a measurable amount reached human blood. Those are separate questions, and each needs testing.

The name itself adds another problem. FDA found that TB-500 and full-length Tβ4 are often treated as interchangeable online even though they differ in length and molecular structure. Without a human absorption study and clear analytical testing, a label reading “TB-500 capsules” is not evidence of delivery or benefit.

Oral BPC-157 is a different evidence question

It is tempting to reason that if one peptide has oral data, another one should behave the same way. That does not follow. Oral BPC-157 has animal studies using oral or stomach-delivered routes. It still lacks controlled human capsule trials, but those animal experiments at least studied the route itself. TB-500 does not have that bridge. Evidence about one peptide's stability cannot be transferred to another peptide by analogy.

FDA status, prescribed care, and competitive sport

TB-500 has never been FDA-approved in the United States, and the compounded formulation offered here is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness, or quality before they are dispensed. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

The agency's May briefing, prepared for a July 23 Pharmacy Compounding Advisory Committee meeting, found no human clinical study, human exposure data, or human safety data for TB-500 by any route. The committee discussion concerned whether TB-500 free base and acetate should be added to the federal 503A bulks list, a list relevant to traditional prescription compounding. FDA says committee recommendations are advisory, not final agency decisions.

For tested athletes, the rule is simpler. The 2026 World Anti-Doping Agency list names TB-500 under growth factors and modulators. It is prohibited at all times, in and out of competition.

Promise lists prescribed TB-500 as an injectable vial, not an oral capsule. An injectable route avoids digestion, but that does not create human outcome evidence for TB-500. It changes the delivery question and adds injection-specific risks that a clinician must weigh. At Promise, a licensed provider reviews every request, and not everyone qualifies.

The honest next step is not to treat capsules and injections as interchangeable. It is to ask what molecule is actually being dispensed, which route has been prescribed, what the pharmacy label documents, and what uncertainty remains. That conversation belongs with a clinician who can review the whole health picture.